Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Pancreatic Neoplasms 3Melanoma 2Breast Neoplasms 2Prostatic Neoplasms 1Prostate Cancer Recurrent 1Pancreatic Ductal Adenocarcinoma 1Osteosarcoma 1Neoplasm, Residual 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1

Interventions

Cyclophosphamide 9X-Rays 8Specimen Handling 8Phantoms, Imaging 7fludarabine 6Magnetic Resonance Spectroscopy 6cabozantinib 5Gemcitabine 5Biopsy 5Nuclear Medicine Department, Hospital 4Methotrexate 4Doxorubicin 4fludarabine phosphate 3Ifosfamide 3Cisplatin 3ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2pembrolizumab 2palbociclib 2olaparib 2mifamurtide 2larotrectinib 2ivosidenib 2irinotecan sucrosofate 2ensartinib 2atezolizumab 2Vincristine 2Temozolomide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Osteosarcoma × Hydroxychloroquine × 90 days × Clear all
NCT03598595 2026-05-14

Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
31 enrolled
Sarcoma

Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡